No association between genetic polymorphisms in NAD(P)H oxidase p22 phox and paraoxonase 1 and colorectal cancer risk

Anticancer Research

Volumn 25, Issue 2 B, 2005, Pages 1465-1470

  Van Der Logt, Elise M J ^a   Janssen, Cynthia H J M ^a   Van Hooijdonk, Zairah ^a   Roelofs, Hennie M J ^a   Wobbes, Theo ^a   Nagengast, Fokko M ^a   Peters, Wilbert H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal cancer; Genetic polymorphisms; NAD(P)H oxidase p22phox paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE; GENOMIC DNA; PROTEIN P22; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ADULT; ARTICLE; CANCER RISK; COLORECTAL CANCER; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ARYLDIALKYLPHOSPHATASE; COLORECTAL NEOPLASMS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NADPH DEHYDROGENASE; NADPH OXIDASE; PHOSPHOPROTEINS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 17444386002     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Houlston RS and Peto J: Genetics of common cancers. In: Inherited Predisposition to Cancer (Eeles RA, Ponder B, Easton DE, Horwich A, eds). London, Chapman Hall Medical, pp 208-226, 1996.
2. Greenwald P, Clifford CK and Milner JA: Diet and cancer prevention. Eur J Cancer 37: 948-965, 2001.
3. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS and Hainaut P: Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21: 7435-7451, 2002.
4. Cho E, Smith-Warner SA, Ritz J, van den Brandt PA, Colditz GA, Folsom AR, Freudenheim JL, Giovannucci E, Goldbohm RA, Graham S, Holmberg L, Kim DH, Malila N, Miller AB, Pietinen P, Rohan TE, Sellers TA, Speizer FE, Willett WC, Wolk A and Hunter DJ: Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med 140: 603-613, 2004.
5. de Jong MM, Nolte IM, te Meerman GJ, van der Graaf WT, de Vries EGE, Sijmons RH, Hofstra RMW and Kleibeuker JH: Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev 11: 1332-1352, 2002.
6. Goldstein BD and Witz G: Free radicals and carcinogenesis. Free Radic Res Commun 11: 3-10, 1990.
7. Wiseman H and Halliwell B: Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 313: 17-29, 1996.
8. Klaunig JE and Kamendulis LM: The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44: 239-267, 2004.
9. Babior BM: Phagocytes and oxidative stress. Am J Med 109: 33-44, 2000.
10. Perner A, Andresen L, Pedersen G and Rask-Madsen J: Superoxide production and expression of NAD(P)H oxidases by transformed and primary human colonic epithelial cells. Gut 52: 231-236, 2003.
11. Inoue N, Kawashima S, Kanazawa K, Yamada S, Akita H and Yokoyama M: Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 97: 135-137, 1998.
12. Taniyama Y and Griendling KK: Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42: 1075-1081, 2003.
13. Babior BM: NADPH oxidase: an update. Blood 93: 1464-1476, 1999.
14. Wyche KE, Wang SS, Griendling KK, Dikalov SI, Austin H, Rao S, Fink B, Harrison DG and Zafari AM: C242T CYBA polymorphism of the NADPH oxidase is associated with reduced respiratory burst in human neutrophils. Hypertension 43: 1246-1251, 2004.
15. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL and La Du BN: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101: 1581-1590, 1998.
16. Nevin DN, Zambon A, Furlong CE, Richter RJ, Humbert R, Hokanson JE and Brunzell JD: Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol 16: 1243-1249, 1996.
17. Draganov DI and La Du BN: Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol 369: 78-88, 2004.
18. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J and Furlong CE: The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14: 334-336, 1996.
19. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C and La Du BN: Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 28: 1335-1342, 2000.
20. Jakubowski H: Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 275: 3957-3962, 2000.
21. Mackness MI, Arrol S, Abbott C and Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104: 129-135, 1993.
22. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM and Navab M: Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96: 2882-2891, 1995.
23. Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P and Ruiz J: Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99: 62-66, 1997.
24. Leviev I, Negro F and James RW: Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 17: 2935-2939, 1997.
25. Leviev I, Deakin S and James RW: Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res 42: 528-535, 2001.
26. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ and Furlong CE: Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10: 767-779, 2000.
27. Mackness B, Mackness MI, Arrol S, Turkie W and Durrington PN: Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423: 57-60, 1998.
28. Wheeler JG, Keavney BD, Watkins H, Collins R and Danesh J: Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363: 689-695, 2004.
29. Leus FR, Wittekoek ME, Prins J, Kastelein JJP and Voorbij HAM: Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia. Atherosclerosis 149: 371-377, 2000.
30. Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N and Spencer A: Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br J Haematol 118: 477-481, 2002.
31. Akcay MN, Polat MF, Yilmaz I and Akcay G: Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 50(Suppl 2): 225-227, 2003.
32. Akcay MN, Yilmaz I, Polat MF and Akcay G: Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 50(Suppl 2): 273-275, 2003.
33. Van der Logt EMJ, Bergevoet SM, Roelofs HMJ, van Hooijdonk Z, te Morsche RHM, Wobbes T, de Kok JB, Nagengast FM and Peters WHM: Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk. Carcinogenesis 25: 2407-2415, 2004.
34. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ and Furlong CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3: 73-76, 1993.
35. Kemp Z, Thirlwell C, Sieber O, Silver A and Tomlinson I: An update on the genetics of colorectal cancer. Hum Mol Genet 13(Spec No 2): R177-R185, 2004.
36. Nebert DW: Drug-metabolizing enzymes, polymorphisms and interindividual response to environmental toxicants. Clin Chem Lab Med 38: 857-861, 2000.
37. Gardemann A, Mages P, Katz N, Tillmanns H and Haberbosch W: The p22 phox A640G gene polymorphism but not the C242T gene variation is associated with coronary heart disease in younger individuals. Atherosclerosis 145: 315-323, 1999.
38. Gardemann A, Philipp M, Hess K, Katz N, Tillmanns H and Haberbosch W: The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 152: 421-431, 2000.
39. Deakin SP and James RW: Genetic and environmental factors modulating serum concentrations and activities of the anti-oxidant enzyme, paraoxonase-1. Clin Sci 107: 435-447, 2004.
40. Costa LG, Cole TB and Furlong CE: Polymorphisms of paraoxonase (PON1) and their significance in clinical toxicology of organophosphates. J Toxicol Clin Toxicol 41: 37-45, 2003.